Treatment-Free Remission in CML: Emerging Data and Considerations for Treatment Selection
Oncology Scientific Exchange Virtual Expert Forum
Basel, Switzerland
6 July 2017

Learning objectives

- Discuss emerging data from longer-term follow-up in clinical studies of TFR
- Discuss the benefit/risk profiles of TKIs and key considerations for treatment selection, including the potential for TFR

Start Time	Duration (min)	Title	Faculty	Key Discussion Points
9:00 AM	05	Session introduction	Timothy Hughes	• Session introduction, including interactive audience features

9:05 AM	05	TFR in guidelines and labels: moving from investigational to clinical practice	Timothy Hughes	• Overview of current TFR recommendations
				  o NCCN guidelines update (v2.2017)
				  o Expected update to ELN guidelines (if information is available)
				  o Other regional/country guidelines (if information is available)
				• Overview of TFR in TKI labels
				  o Eg, Tasigna EMA label

9:10 AM	15	Longer-term follow-up of TFR trials: STIM1, EURO-SKI, STOP 2G-TKI, and DADI	Delphine Rea	• Specific topics may include:
				  o Rate of late relapses
				  o KM curves: is there a plateau?
				  o Regaining molecular response after relapse
				  o Safety and adverse events

9:25 AM	25	Longer-term follow-up of TFR trials: ENESTfreedom and ENESTop	Timothy Hughes	• Specific topics may include:
				  o Rate of late relapses
				  o KM curves: is there a plateau?
				  o Regaining molecular response after relapse
				  o Safety and adverse events

9:50 AM	20	Benefit/risk and selection of TKIs	Giuseppe Saglio	• Benefit/risk profiles of TKIs and selection of front- and second-line therapy, taking TFR into consideration
10:10 AM	15	Q&A	All	• Interactive, real-time Q&A
10:25 AM	05	Meeting summary & close	Timothy Hughes	• Summary and closing remarks